LAVA Therapeutics Appoints Dr. Charles Morris As Chief Medical Officer
(RTTNews) - Immuno-oncology company LAVA Therapeutics N.V. (LVTX) announced Monday that Dr. Charles Morris has joined LAVA as chief medical officer effective February 6, 2023. Dr. Morris will replace Benjamin Winograd.
Dr. Morris is a medical oncologist with over 25 years of oncology drug development experience working with global biotech and pharmaceutical companies and managing numerous drug approvals.
Most recently, he was the chief medical officer for biotechnology company Celyad Oncology. He also served as chief medical officer of Radius Health and held leadership positions at PsiOxus Therapeutics, ImmunoGen and Allos Therapeutics.
He was also vice president of worldwide clinical research at Cephalon where he supported the approval of TREANDA (bendamustine) for the treatment of indolent non-Hodgkin lymphoma and chronic lymphocytopenia.
He began his career at AstraZeneca and held roles of increasing responsibility including global medical lead for Faslodex (fulvestrant) which he managed through its approval for breast cancer.
Seagen, LAVA Therapeutics Ink Worldwide License Agreement To Develop And Commercialize LAVA-1223
Slightly Weak Start Seen For U.S. Stocks; PCE Data In Focus
Lower Futures Pointing To Weak Start On Bay Street; Canadian GDP, US PCE Data In Focus
Pound Slides Against Majors
FTSE 100 Weak Again, Looks Headed For Weekly Loss
Pound Falls Against Majors
French Stocks Mostly Subdued In Cautious Trade
